UBS Global Biopharma Conference - DENALI THERAPEUTICS INC
Financial Performance:
- Q3 2026 revenue reached ~$18 million, significantly exceeding the prior $10–12 million guidance and consensus estimates.
- Revenue growth was driven by accelerated payer access (commercial and Medicaid) and an earlier-than-expected influx of E2 clinical trial patients switched to treatment.
- Q4 2026 guidance is set between $30–32 million.
- Management estimates ~95% of the US Hunter syndrome patient population is currently treated with competitor Elaprase, providing a large base for patient switching.
- Total US Hunter syndrome market size is 500 patients, with 375 eligible per FDA label; the goal is to capture the majority (market leadership) by 2027.
- The company expects strong growth trajectory from 2026 to 2027, citing high persistence rates typical of rare disease therapies.
- Future pipeline programs (G6PC3, GBA, Pompe, FTD) are projected to generate $3–4 billion in peak revenue.
- In-house manufacturing capabilities are being scaled to reduce COGS for future products like Zafi (Sanfilippo), though Avala (Hunter) remains with Lonza to meet volume demands.
Guidance and Future Outlook:
- Management provided quarterly guidance for Q4 2026 ($30–32 million) but has not yet decided on long-term annual guidance.
- The company targets becoming the market leader in Hunter syndrome by 2027, aiming to capture the majority of the eligible patient pool.
- The COMPASS confirmatory study for Avala is expected to complete its primary cohort (Cohort A) by the end of 2027, with data release targeted for the first half of 2028.
- 2027 is a pivotal year for the Alzheimer's pipeline, with Phase 1b data (MAP-T and A-beta) expected to be released to identify optimal dosing.
- Long-term goals include expanding Avala's label via COMPASS data to access international markets outside the US (targeting the "last third" of the market).
- Management anticipates the Avala launch curve will inflect sooner than typical rare disease "S-curves" due to strong early momentum.
Business Segments and Product Lines:
- Avala (Hunter Syndrome): First commercial product; validates the transport vehicle platform. Strong real-world feedback on clinical efficacy and safety.
- Zafi (Sanfilippo Type A): Phase 3 pivotal data (49-week portion) prepared for data lock in Q4 2026; data presentation scheduled for World 2027 (February). Manufacturing is in-house at the US facility.
- Alzheimer's Pipeline: Two programs in Phase 1b targeting A-beta and Tau (MAP-T).
- MAP-T: Uses an ASO delivered via IV (transferrin receptor shuttle) to achieve even brain distribution, contrasting with the uneven distribution of intrathecal delivery used by competitors like Biogen.
- A-beta: Focus on enhancing plaque reduction and enabling subcutaneous (Sub-Q) administration to reduce infusion-related reactions and hematological issues seen with naked antibodies (e.g., Roche's Tiotinamab).
- Other Enzyme Programs: Pipeline includes Pompe (G6PC3), Gaucher (GBA), and FTD (granules), utilizing the same transport vehicle technology.
Market and Competitive Landscape:
- Hunter Syndrome: 95% of eligible patients currently on Elaprase; competitors are primarily enzyme replacement therapies (ERTs).
- Sanfilippo: Ultragenyx's gene therapy approved previously shows ~50-60% CSF heparan sulfate reduction but lacks robust peripheral effects and one-time durability; Denali's Zafi aims for robust reduction in both brain and periphery.
- Alzheimer's: Competitors include Biogen (naked ASO for Tau), Roche (Tiotinamab A-beta), and others like Cursana.
- Differentiation: Denali's platform allows for IV administration (versus intrathecal), achieving even CNS distribution and higher uptake compared to intrathecal injections; aims for Sub-Q dosing in Alzheimer's.
- Market Size: Denali views the platform as applicable to multi-billion dollar indications like Alzheimer's, leveraging the validated A-beta and Tau targets.
Risks and Challenges:
- Confirmatory Study Uncertainty: The COMPASS study requires statistical significance; management acknowledges risk regarding natural history of the disease and potential placebo/competitor decline dynamics.
- Manufacturing Capacity: Transitioning to in-house manufacturing requires rigorous scaling; while Zafi will use the new facility, Avala relies on Lonza due to current volume requirements (scaling from 2,000L to 6,000L).
- Clinical Trial Complexity: Ultra-rare disease populations make study powering difficult; natural history data is critical for interpreting trial outcomes.
- Competitive Data: Biogen's Tau data showed an inverse dose relationship in primary endpoints (CDR-SB), though secondary endpoints showed significance; Denali must prove superior biological impact (even distribution) to outperform.
- Regulatory Hurdles: International approval requires randomized controlled trial data (COMPASS), delaying market expansion beyond the US until 2028.
Management Commentary and Tone:
- Tone is highly confident and optimistic, describing 2026 as a "transformative year" with the successful launch of Avala.
- Management emphasizes the validation of the transport vehicle platform, viewing Avala as the foundation for a robust enzyme replacement business to fund broader pipeline development.
- Strong belief in the "platform" approach, projecting multiple billion-dollar opportunities across rare diseases and Alzheimer's.
- Management expressed clear strategic vision to move from in-house manufacturing for future products to a self-sufficient commercial entity.
- Acknowledged the stock volatility but remained focused on the execution of the launch and pipeline progression.
Analyst Questions and Answers:
- Q: Breakdown of revenue (new vs. switch)? A: Majority of patients are switching from Elaprase; 95% of the prevalent Hunter population is already on ERT.
- Q: Confidence in COMPASS study hitting primary endpoints? A: Confidence is high based on prior data and biomarker reductions, but not quantified as 90% due to the ultra-rare nature of the disease and the need for statistical significance.
- Q: Timeline and regulatory path for Sanfilippo (Zafi)? A: Pivotal data lock prepared; filing timing driven by module 3 (manufacturing) readiness. In-house manufacturing is a key advantage.
- Q: Differentiation between Denali's Tau program and Biogen's? A: Denali uses IV delivery with a shuttle for even brain distribution vs. Biogen's intrathecal delivery (uneven). Goal is to achieve 30-60% Tau reduction with even distribution.
- Q: Timeline for Alzheimer's data? A: Phase 1b data for both MAP-T and A-beta expected in 2027, including CSF Tau reduction and PET Tau imaging.
- Q: Can Hunter be moved to in-house manufacturing? A: Currently not feasible due to volume scaling needs (2,000L to 6,000L); Lonza partnership remains for Avala.
Other Key Points:
- The COMPASS study has two cohorts: Cohort A (neurologic) and Cohort B (systemic); Cohort A is the rate-limiting step for 2028 data readout.
- Denali plans to expand the Avala label to include international markets following the COMPASS study results.
- The company is focusing on Sub-Q delivery for Alzheimer's assets to improve patient convenience and reduce infusion risks.
- Management highlighted the "S-shaped" launch curve, noting the inflection point is arriving sooner than historically observed in rare diseases.
- The company views the Enzyme Replacement Therapy (ERT) business as a cash cow capable of funding the high-risk, high-reward Alzheimer's pipeline.
- Company
- DENALI THERAPEUTICS INC
- Keywords
- DENALI THERAPEUTICS INC